MBRX: Moleculin Biotech, Inc. Stock

by  •  • Comments Off on MBRX: Moleculin Biotech, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 11.43
Enterprise Value ($M) -12.12
Book Value ($M) 26.07
Book Value / Share 11.70
Price / Book 0.44
NCAV ($M) 14.13
NCAV / Share 6.34
Price / NCAV 0.81

Profitability (mra)
Return on Invested Capital (ROIC) -1.12
Return on Assets (ROA) -0.58
Return on Equity (ROE) -0.65

Liquidity (mrq)
Quick Ratio 3.86
Current Ratio 3.86

Balance Sheet (mrq) ($M)
Current Assets 26.27
Assets 38.22
Liabilities 12.14
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -29.63
Net Income -29.77
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -24.10
Cash from Investing -0.12
Cash from Financing 4.65

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99 231.62

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 2,329 16,521 14.10
2024-05-02 672 1,005 66.87
2024-05-01 4,438 5,400 82.19
2024-04-30 4,157 5,176 80.31

(click for more detail)

Similar Companies
LSTA – Lisata Therapeutics, Inc. LTRN – Lantern Pharma Inc.
MBIO – Mustang Bio, Inc. MEIP – MEI Pharma, Inc.
MIRA – MIRA Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Moleculin Biotech